Want to see CRDF full AI Analyst Report?
CRDF Stock Chart & Stats
$1.80
-$0.21(-4.99%)
At close: 4:00 PM EST
$1.80
-$0.21(-4.99%)
Day’s Range― - ―
52-Week Range$1.16 - $4.56
Previous CloseN/A
Volume446.20K
Average Volume (3M)1.54M
Market Cap
$90.25M
Enterprise Value$72.78M
Total Cash (Recent Filing)$46.06M
Total Debt (Recent Filing)$646.00K
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Jul 30, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding68,369,896
10 Day Avg. Volume1,386,998
30 Day Avg. Volume1,542,867
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue138.63
Enterprise Value/Gross Profit-6.58
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$6.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$239.44K
Bulls Say, Bears Say
Bulls Say
Registrational Path From Phase 2Robust interim Phase 2 efficacy (72% ORR) and a successful end‑of‑Phase 2 regulator meeting materially raise the probability of a defined Phase 3 plan and potential accelerated approval. This improves the long‑term commercial pathway and resource allocation clarity for onvansertib.
Low Financial LeverageVery low debt provides financial flexibility and reduces bankruptcy risk during clinical development. For a cash‑burning biotech, minimal leverage preserves optionality to raise capital through equity or collaborations without heavy interest burdens, a durable balance sheet strength.
Board & Incentive SupportStrong shareholder backing of the board, auditor continuity, and approval of an expanded equity incentive plan supports governance stability and talent retention. That continuity aids long‑term execution of clinical programs and reduces leadership turnover risk during crucial trial periods.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow at ~-$37M annually requires recurring external financing to fund trials. This persistent burn pressures liquidity, creates dilution risk, and forces management to prioritize capital calls or partnerships over optional R&D investments.
Minimal Revenue & Large LossesPractically no recurring revenue and large, sustained operating losses indicate no internal cash generation buffer. The business remains fully dependent on external capital and clinical success to reach breakeven, making execution and trial outcomes critical to long‑term viability.
Material IP/License DisputeActive litigation and a termination threat over the onvansertib license endanger Cardiff’s control of its lead asset. An adverse outcome could delay development, increase costs, or jeopardize commercialization rights—fundamentally undermining the company’s core value driver.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $1.16 and its highest was $4.55 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $90.25M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 18 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on May 14, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.135 by -$0.045.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 68,369,896 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.135. Following the earnings report the stock price went down -3.468%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (233.33% Upside)
$6.00 (233.33% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 10.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $66.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.02%
12-Months-Change
Fundamentals
Return on Equity
-95.50%
Trailing 12-Months
Asset Growth
-42.02%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
CRDF Stock 12 Month Forecast
Average Price Target
$6.00
▲(233.33% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
2.28% Insiders
7.94% Mutual Funds
1.12% Other Institutional Investors
83.63% Public Companies and
Individual Investors